Ibogaine

Iboga, ibogaine, noribogaine & 18-MC

 

 

Jump to:

Page 6 (2013-2017)

 
 

 

Mazoyer et al. (2013). Fatal case of a 27-year-old male after taking iboga in withdrawal treatment: GC-MS/MS determination of ibogaine and ibogamine in iboga roots and postmortem biological material. Journal of Forensic Sciences.

O’Connell, Gerona & Ly (2013). A case of acute ibogaine toxicity confirmed with serum and urine levels and product contents. Clinical Toxicology.

Papadodima et al. (2013). Ibogaine related sudden death: A case report. Journal of Forensic and Legal Medicine.

Chauv et al. (2014). QTC prolongation progressing to torsade de pointes secondary to ibogaine ingestion. Critical Care Medicine.

Koenig et al. (2014). anti‐addiction drug ibogaine inhibits hERG channels: A cardiac arrhythmia risk. Addiction Biology.

Meyer et al. (2014). A qualitative/quantitative approach for the detection of 37 tryptamine-derived designer drugs, 5 beta-carbolines, ibogaine, and yohimbine in human urine and plasma using standard urine screening and multi-analyte approaches. Analytical and Bioanalytical Chemistry.

Schenberg et al. (2014). Treating drug dependence with the aid of ibogaine: A retrospective study. Journal of Psychopharmacology.

Tang et al. (2014). Iboga-type alkaloids from Ervatamia officinalis. Journal of Natural Products.

Terada et al. (2014). Identification of indole alkaloid structural units important for stimulus-selective TRPM8 inhibition: SAR study of naturally occurring iboga derivatives.

Thurner et al. (2014). Mechanism of hERG channel block by the psychoactive indole alkaloid ibogaine. The Journal of Pharmacology and Experimental Therapeutics.

Vlaanderen et al. (2014). Cardiac arrest after ibogaine ingestion. Clinical Toxicology.

Arias et al. (2015). Coronaridine congeners inhibit human α3β4 nicotinic acetylcholine receptors by interacting with luminal and non-luminal sites. The International Journal of Biochemistry & Cell Biology.

Breuer et al. (2015). "Herbal seizures"--atypical symptoms after ibogaine intoxication: a case report. Journal of Medical Case Reports.

Chang et al. (2015). Noribogaine reduces nicotine self-administration in rats. Journal of Psychopharmacology.

Glue et al. (2015). Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20 mg dose of ibogaine in healthy volunteers. Journal of Clinical Pharmacology.

Glue et al. (2015). Ascending-dose study of noribogaine in healthy volunteers: pharmacokinetics, pharmacodynamics, safety, and tolerability. Journal of Clinical Pharmacology.

Koenig & Hilber (2015). The anti-addiction drug ibogaine and the heart: a delicate relation. Molecules.

Kruegel et al. (2015). Constructing lboga alkaloids via c-h bond functionalization: examination of the direct and catalytic union of heteroarenes and isoquinuclidine alkenes.

Maillet et al. (2015). Noribogaine is a G-protein biased κ-opioid receptor agonist. Neuropharmacology.

Marta et al. (2015). Mania following use of ibogaine: A case series. The American Journal on Addictions.

Nikolić-Kokić et al. (2015). Ex vivo effects of ibogaine on the activity of antioxidative enzymes in human erythrocytes. Journal of Ethnopharmacology.

O’Connell et al. (2015). Internet-purchased ibogaine toxicity confirmed with serum, urine, and product content levels. American Journal of Emergency Medicine.

Ohishi et al. (2015). Coronaridine, an iboga type alkaloid from Tabernaemontana divaricata, inhibits the Wnt signaling pathway by decreasing β-catenin mRNA expression. Bioorganic & Medicinal Chemistry Letters.

Alper et al. (2016). hERG blockade by iboga alkaloids. Cardiovascular Toxicology.

Authier et al. (2016). Functional neurotoxicity evaluation of noribogaine using video-EEG in cynomolgus monkeys. Journal of Pharmacological and Toxicological Methods.

Belgers et al. (2016). Ibogaine and addiction in the animal model, a systematic review and meta-analysis. Translational Psychiatry.

Brunt & Litjens (2016). In reply - on the toxicity of ibogaine. Clinical Toxicology.

Chen et al. (2016). Cytotoxic monoterpenoid indole alkaloids isolated from the barks of Voacanga africana Staph. Natural Product Research.

Cloutier-Gill et al. (2016). Remission of severe opioid use disorder with ibogaine: A case report. Journal of Psychoactive Drugs.

Eggan & McCallum (2016). 18-Methoxycoronaridine acts in the medial habenula to attenuate behavioral and neurochemical sensitization to nicotine. Behavioural Brain Research.

Forsyth et al. (2016). Effects of low dose ibogaine on subjective mood state and psychological performance. Journal of Ethnopharmacology.

Gassaway et al. (2016). Deconstructing the iboga alkaloid skeleton: potentiation of FGF2-induced glial cell line-derived neurotrophic factor release by a novel compound. ACS Chemical Biology.

Gicquel et al. (2016). Death related to consumption of Rauvolfia sp. powder mislabeled as Tabernanthe iboga. Forensic Science International.

Glue et al. (2016). Ascending single-dose, double-blind, placebo-controlled safety study of noribogaine in opioid-dependent patients. Clinical Pharmacology in Drug Development.

Hanneman, Oberle & Carlos (2016). Ibogaine toxicity in a case of good intentions. American Journal of Respiratory and Critical Care Medicine.

Hildyard et al. (2016). A case of QT prolongation and torsades de pointes caused by ibogaine toxicity. Journal of Emergency Medicine.

Krengel et al. (2016). Quantification of anti-addictive alkaloids ibogaine and voacangine in in vivo- and in vitro-grown plants of two Mexican Tabernaemontana species. Chemistry & Biodiversity.

Litjens & Brunt (2016). How toxic is ibogaine? Clinical Toxicology.

Mash et al. (2016). Oral noribogaine shows high brain uptake and anti-withdrawal effects not associated with place preference in rodents. Journal of Psychopharmacology.

Meisner et al. (2016). Ibogaine-associated cardiac arrest and death: case report and review of the literature. Therapeutic Advances in Psychopharmacology.

Nge et al. (2016). Ibogan, Aspidosperman, Vincamine, and Bisindole Alkaloids from a Malayan Tabernaemontana corymbosa: Iboga Alkaloids with C-20α Substitution. Journal of Natural Products.

Paterna et al. (2016). Vobasinyl-iboga alkaloids from Tabernaemontana elegans: cell cycle arrest and apoptosis-inducing activity in HCT116 colon cancer cells. Journal of Natural Products.

Rezvani et al. (2016). Acute oral 18-methoxycoronaridine (18-MC) decreases both alcohol intake and IV nicotine self-administration in rats. Pharmacology, Biochemistry and Behavior.

Schep et al. (2016). Ibogaine for treating drug dependence. What is a safe dose? Drug and Alcohol Dependence.

Yip & Deng (2016). On the toxicity of ibogaine. Clinical Toxicology.

Zdrojewicz et a. (2016). [Ibogaine - structure, influence on human body, clinical relevance]. Polski Merkuriusz Lekarski.

Zhao et al. (2016). Bioinspired collective syntheses of iboga-type indole alkaloids. Organic Letters.

Arias et al. (2017). Selectivity of coronaridine congeners at nicotinic acetylcholine receptors and inhibitory activity on mouse medial habenula. International Journal of Biochemistry & Cell Biology.

Asjad et al. (2017). Pharmacochaperoning in a Drosophila model system rescues human dopamine transporter variants associated with infantile/juvenile parkinsonism. The Journal of Biological Chemistry.

Heink, Katsikas & Lange-Altman (2017). Examination of the phenomenology of the ibogaine treatment experience: Role of altered states of consciousness and psychedelic experiences. Journal of Psychoactive Drugs.

Henstra et al. (2017). Toxicokinetics of ibogaine and noribogaine in a patient with prolonged multiple cardiac arrhythmias after ingestion of internet purchased ibogaine. Clinical Toxicology.

Kalueff, Kaluyeva & Mailet (2017). Anxiolytic-like effects of noribogaine in zebrafish. Behavioural Brain Research.

Kubiliene et al. (2017). Investigation into pharmacokinetic properties of active alkaloid ibogaine and its metabolite noribogaine. Acta Poloniae Pharmaceutica.

Rubi et al. (2017). Anti-addiction drug ibogaine prolongs the action potential in human induced pluripotent stem cell-derived cardiomyocytes. Cardiovascular Toxicology.